Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714713 · ClinicalTrials.gov registry record · Phase 3
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
NCT01714713 is a Phase 3 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 830 participants.
The verdict
NCT01714713, a Phase 3 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
Study Summary
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.
Interventions
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714713
The ClinicalTrials.gov registry entry for NCT01714713 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 830 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVP-6124 is the first listed.
NCT01714713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01714713 about?
NCT01714713 is a clinical study titled "A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.
What is the current status of trial NCT01714713?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2013-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01714713?
The interventions under investigation include: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT01714713?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.